Delivery Order V797D40230-36C25623F0357
Award Date
9/29/23
Potential Completion Date
10/31/23
Potential Value
$96K
Federal Agency
Veterans Integrated Service Network 16
Awardee
Regenesis Biomedical Inc.
Ultimate Awardee
Not listed
NAICS Category
339112 - Surgical and Medical Instrument Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Scottsdale, AZ 85250, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $3,645.14 firm fixed-price purchase order is for the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical. The contract has an ultimate completion date of March 25, 2011. This award was made against Regenesis Biomedical's General Services Administration (GSA) Schedule 65-II-A...
This is a federal contract award to Regenesis Biomedical Inc., a medical technology company, by the Department of Veterans Affairs (VA) under the Veterans Integrated Service Network 17 (VISN 17). The contract is for the provision of the Provant Therapy System, a non-invasive regenerative medicine product, for use in VA medical facilities. The contract has a firm fixed price of $4,820.98 and is not designated as a set-aside. The award is likely made against Regenesis Biomedical's existing General...
This federal contract award to Regenesis Biomedical Inc. is for the supply of the company's Provant Therapy System medical device and related rental/leasing services to the U.S. Department of Veterans Affairs (VA). The $4,882.79 firm-fixed-price purchase order was awarded on February 16, 2011, with a completion date of March 16, 2011. The contract was awarded against Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A contract for medical equipment and...
This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical device manufacturer, for $7,142.85. The contract is for the supply and rental of Regenesis' Provant Therapy System, a non-invasive regenerative medicine product, to VA medical facilities. The contract has an ultimate completion date of May 6, 2011 and was awarded on April 6, 2011. This purchase order was issued under Regenesis' existing General...
This federal contract award is for the purchase of the Provant Therapy System from Regenesis Biomedical Inc., a medical technology company. The $4,820.98 firm fixed-price purchase order was awarded by the U.S. Department of Veterans Affairs (VA) on December 28, 2010, with an ultimate completion date of January 28, 2011. The contract was awarded against Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies, and did not utilize any set-aside designations....
This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a manufacturer of medical devices. The $4,820.98 firm fixed-price purchase order was for the Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract was awarded under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies, which the company has...
This federal contract award is for the provision of the Provant Therapy System by Regenesis Biomedical Inc. to the Department of Veterans Affairs (VA). The Provant Therapy System is a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract, valued at $10,067.09, is a firm fixed-price purchase order with no set-aside designation. Regenesis Biomedical Inc. acts as the prime contractor, providing the Provant Therapy System...
This is a $3,645.14 firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc. for the Provant Therapy System, a noninvasive regenerative medicine product. The contract is not set-aside and was awarded under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies. The Provant Therapy System is indicated for palliative treatment of post-operative pain and edema, and Regenesis Biomedical appears to be the...
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company, for the Provant Therapy System. The contract, valued at $4,992.40, is for the provision of the Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is not associated with a set-aside program and appears to be part of Regenesis...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm-fixed-price purchase order is for the company's Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of May 8, 2011 and was awarded through Regenesis Biomedical's existing GSA Schedule...